Sign in with Google
bearish
Obi Pharma Inc (4174 TT): Inherent Pipeline Risk Has Clouded Near-Term Outlook
534 Views20 Jan 2023 15:22
SUMMARY
- Obi Pharma Inc (4174 TT) is developing novel therapeutic agents for unmet medical needs against cancers. The company’s lead pipeline candidate, adagloxad simolenin is a first-in-class cancer vaccine candidate.
- Currently, adagloxad simolenin is in phase 3 study as an adjuvant treatment of high-risk, early-stage, Globo H-positive triple negative breast cancer, which represents 15–20% of breast cancer cases.
- The company has a cash runway through 2024, while phase 3 trial is expected to be completed in 2025. With the pipeline progress, operating expenses are expected to increase.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- HEW: Doves Disappointed By Patience
- East Buy Holdings (1797 HK): Potential KWEB Deletion in June
- [Japan Activism] ISS Comes Out Supporting Orbis Against Tsuruha/Welcia Merger Ratio
- [Japan M&A] NTT (9432) Overpays To Buy Out NTT Data (9613) Minorities
- StubWorld: Geely Is (Mostly) Trading "Rich"; And May Still Bump Zeekr Terms
Top Unpaywalled Insights
More »- The Polycrisis Era (2025–2028): Navigating a World of Overlapping Disruptions
- Our AI-Powered Accounting Risk Trading Strategy Beat the S&P 500 by 2.5x
- India-UK Free Trade Agreement: A New Era for India's Textile Industry
- The Rise of Quant Investing in Crypto w/ Truvius CEO Connor Farley | The New Barbarians #007
- New Research: Unlocking Quantitative Alpha in Cryptocurrency Markets
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
x